DB 1312
Alternative Names: Antibody drug conjugate - DualityBio/BeOne Medicines; BG-C9074; DB-1312Latest Information Update: 11 Jun 2025
At a glance
- Originator Duality Biologics
- Developer BeOne Medicines; Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jun 2025 Interim adverse events, efficacy and pharmacokinetics data from a phase-I trial in Solid tumours released by BeOne Medicines
- 30 Dec 2024 BeiGene in-licenses DB 1312 from Duality Biologics
- 12 Apr 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia (IV) (NCT06233942)